室内细颗粒物暴露对特发性肺纤维化进展影响的前瞻性多中心队列研究方案
本研究为前瞻性多中心队列研究,在韩国15家医疗机构招募120例特发性肺纤维化(IPF)患者并随访1年,评估室内PM2.5暴露对疾病进展、住院、急性加重和死亡的影响。通过连续室内空气质量监测和定期肺功能检查,结合生物标志物分析,探讨室内颗粒物暴露与IPF临床结局的关联。
要点
- 室内PM2.5暴露可能影响IPF疾病进展,但此前数据有限。
- 研究纳入120例IPF患者,随访1年,评估肺功能下降、住院、急性加重和死亡。
- 采用连续室内PM2.5监测和 quarterly 肺功能检查,部分患者每日家庭肺功能监测。
核心结论
- 研究旨在评估室内PM2.5暴露对IPF进展的影响,目前为研究方案,尚无结论。
研究设计与样本
- 前瞻性多中心队列研究,在韩国15家医疗机构招募120例IPF患者,随访1年。
关键数值与推荐
- 疾病进展定义为用力肺活量相对下降≥10%或一氧化碳弥散量相对下降≥15%。
- 室内PM2.5水平使用散射式室内空气质量监测仪(IAQ-CL; KWeather, Seoul, South Korea)连续测量,同时测量PM10、挥发性有机化合物和二氧化碳。
- 肺功能检查每季度在机构进行,部分50例参与者每日进行家庭肺功能监测。
- 生物标志物分析包括Krebs von den Lungen-6及其他相关标志物。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background Idiopathic pulmonary fibrosis (IPF) is a fatal lung disease characterised by progressive fibrosis. Environmental exposures, including fine particulate matter (PM 2.5 ), have been implicated in the progression of IPF; however, indoor data are limited. We aimed to evaluate the impact of indoor exposure to PM 2.5 on the progression of IPF. Methods and analysis This prospective, multicentre cohort study involves 15 medical institutions across South Korea. A total of 120 patients with IPF have been recruited and will be followed for 1 year. The impact of indoor exposure to PM 2.5 on clinical outcomes, including progression of the disease (defined as a relative decline in forced vital capacity ≥10% or diffusing capacity for carbon monoxide ≥15%), hospitalisation, acute exacerbations and mortality, will be assessed. Pulmonary function tests will be conducted quarterly at institutions, with home-based spirometry performed daily in a subset of 50 participants. The indoor PM 2.5 level will be continuously measured using a scattering-based indoor air quality monitor (IAQ-CL; KWeather, Seoul, South Korea) and PM 10 , volatile organic compounds and carbon dioxide will also be measured. Biomarker analysis of Krebs von den Lungen-6 and other related markers will be performed. Statistical analyses will use linear mixed-effects models and time-to-event models to evaluate the association between exposure to PM and clinical and biomarker outcomes. Ethics and dissemination The study has been approved by the Institutional Review Boards of all institutions, including Asan Medical Center (S2021-1136-0051). Written informed consent was obtained from all participants prior to enrolment. Trial registration number KCT0008638.
引用
- BMJ Open Respiratory Research:Impact of indoor exposure to particulate matter on the progression of idiopathic pulmonary fibrosis: a prospective multicentre cohort study protocol
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。